| Literature DB >> 31934451 |
Christopher J Boos1,2,3,4, Norman De Villiers1,2,3, Daniel Dyball1,2, Alison McConnell3, Alexander N Bennett1,5.
Abstract
BACKGROUND AND OBJECTIVES: Cardiovascular disease (CVD) is a leading cause of death among military veterans with several reports suggesting a link between combat and related traumatic injury (TI) to an increased CVD risk. The aim of this paper is to conduct a widespread systematic review and meta-analysis of the relationship between military combat ± TI to CVD and its associated risk factors.Entities:
Year: 2019 PMID: 31934451 PMCID: PMC6942813 DOI: 10.1155/2019/9849465
Source DB: PubMed Journal: Int J Vasc Med ISSN: 2090-2824
Figure 1PRISMA flow diagram representing search and selection of studies.
Description of individual studies and their outcomes and findings.
| Author year | Population | Numbers and type of exposure | Study design | Age in years | Male, % in combat group | Follow up | Outcomes | Key finding/covariate adjustment |
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| Hrubec and Ryder 1980 [ | US military WWII (1944–45) veterans | 3890 proximal amputees | Retrospective cohort | >80% <30 years old at time of injury | 100% | >30 years | All-cause and disease specific mortality | ↑ adjusted all-cause (RR : 1.36 : 1.25–1.48) CVD (RR : 1.58 : 1.40–1.79) and CHD related death (RR : 1.56 : 1.36–1.79) among proximal amputees vs. injured. ↑ risk of all-cause (1.29 : 1.18–1.41), CVD (1.44 : 1.26–1.64) and CHD (1.45 : 1.24–1.68) death among proximal vs distal amputees and vs general population. |
| 2917 distal amputees | ||||||||
| 3 groups age matched | ||||||||
| 3890 injured | Ages at analysis not provided | |||||||
| US population (age matched) | ||||||||
|
| ||||||||
| Labouret et al. 1987 [ | French veterans | 106 with combat related amputation (49 AKA) | Cross-sectional | Compared by age decades from 40–89 years | 100% | >15 years | Systolic and diastolic blood pressure | Higher unadjusted prevalence of systolic (not diastolic) HTN in the amputees vs controls (56% vs. 29%; |
| WWI (1914) | 184 age matched controls without HTN | |||||||
| WWII (1939) | ||||||||
| Other | ||||||||
|
| ||||||||
| Rose et al. 1987 [ | US Vietnam War veterans | 19 AKA | Cross-sectional | 20–22 at injury and 35–36 years at analysis | 100% | ≥;15 years | Insulin response to glucose infusion | ↑ unadjusted rate of HTN (10/19) in amputees vs controls (1/12; |
| 12 age matched controls | ||||||||
|
| ||||||||
| Vollmar et al. 1989 [ | German WWII (1939–1945) veterans | 329 veterans with AKA | Cross-sectional | 67.2 years AKA | 100% | 43.8 years from injury | Ultrasound diagnosis of infrarenal abdominal aortic aneurysms | ↑ AKA in amputees vs controls (5.8% vs. 1.1%); no differences in risk of HTN, hyperlipidemia and DM (comparative data not reported) |
| 702 nonamputee veterans | ||||||||
| 68.1 years controls with comparable burden of CVD risk factors | ||||||||
|
| ||||||||
| Yekutiel et al. 1989 [ | Israeli War Veterans wars (1948–9, 1956, 1967, 1973) | 53 traumatic lower limb amputees | Cross-sectional | 57.2 years | 100% | >20 years from injury | Hypertension, CHD and DM | ↑ unadjusted prevalence of CHD in amputees vs controls (32.1% vs. 18.2%; |
| 159 age and sex-matched controls | ||||||||
|
| ||||||||
| Lorenz et al. 1994 [ | German population conflicts not stated | 226 veterans with traumatic lower limb amputations | Cross-sectional | Age not reported (short report) | Not reported | Unreported but >1 year | Ultrasound diagnosis of abdominal aortic aneurysms | No difference in prevalence of aortic aneurysms among amputees (4.4%) vs controls (4%). No difference in risk of hypertension, diabetes or hyperlipidemia. |
| 199 controls | ||||||||
|
| ||||||||
| Peles et al. 1995 [ | Israel defence force veterans 1948–1974 | 52 Amputees | Cross-sectional | Amputees 52 years controls 53 years | 100% | 33 years after injury | Insulin resistance and autonomic function | Age adjusted ↑ in insulin levels among amputees vs controls; No unadjusted difference in glucose, lipids and blood pressure |
| 53 nonmilitary controls | ||||||||
|
| ||||||||
| Modan et al. 1998 [ | Israeli army wounded 1948–1974 | Cohort 1 201 veterans + traumatic lower limb amputation 1832 general US population | Retrospective cohort study | 50% <40 years | 100% | 24-year | All-cause CVD and non CVD mortality | Two fold ↑ (amputees vs. controls) in unadjusted risk of all-cause (21.9% vs. 12.1% |
| Cohort 2 101 amputees 96 controls (matched by age and ethnicity) | Cross-sectional | |||||||
| CV risk factors | Cohort 2 ↑ plasma insulin levels (2 hour post oral glucose load) in amputees; No differences in unadjusted CHD (19.8% vs. 16.7%), cerebrovascular disease (3.0% vs. 5.2%), obesity, DM, HTN (43.6% vs. 35.4%), hyperlipidemia (37.6% vs. 30.2%) | |||||||
|
| ||||||||
| Shahriar et al. 2009 [ | Iranian wars | 327 bilateral lower limb amputees | Cross-sectional | 42 years at analysis with age of 20.6 years at injury control group age not reported | 100% | Mean 22.3 | Obesity and CVD risk factors | ↑ unadjusted risk of HTN (28.5% vs. 20.4%: |
| Iranian general population (demographics undefined) [ | ||||||||
|
| ||||||||
| Kunnas et al. 2011 [ | Finnish Military WWII veterans | 102 injured combat veterans | Prospective cohort study | 55 years | 100% | 28 years | CHD mortality | (↑ adjusted risk of CHD (HR 1.7 : 1.1–2.5; |
| 565 non injured veterans | ||||||||
|
| ||||||||
| Stewart et al. 2015 [ | US Military Iraq and Afghanistan wars 2002–2011 | 3846 severe traumatic injuries | Retrospective cohort | 25–29.2 years | ≥98% | 1.1–4.3 years | Armed Forces Medical Examiner System (AFMES) database of outcomes | Each 5-point ↑in the ISS linked to a 6%, 13% and 13% ↑ in the adjusted risk of HTN (OR 1.06; 1.02–1.09; |
| Millennium cohort [ | ||||||||
|
| ||||||||
| Ejtahed et al.2017 [ | Iran veterans of Iran-Iraq War | 235 veterans with bilateral traumatic lower limb amputations vs general population | Cross-sectional | 31.5 years at injury and 52 years at follow up | 100% | 32.1 years form injury | Metabolic syndrome | 2-fold ↑ in metabolic syndrome, including HTN, insulin levels, hyperlipidemia and obesity (amputees (62.1%) vs general Iranian population (27.5% ) |
| Age for comparator not reported | ||||||||
|
| ||||||||
|
| ||||||||
| Bullman et al. 1990 [ | US Vietnam War veterans | 6668 high-combat veterans deaths | Retrospective cohort | Similar ages in both groups | 100% | Median follow up >5 years | ICD8 8 codes | ↓ in proportionate CVD mortality vs control group (mortality ratio 0.93 : 0.88–0.98). |
| 27917 low combat veteran deaths | ||||||||
|
| ||||||||
| O'Toole et al. 1996 [ | Australian Vietnam War veterans | 641 army veterans (10.8% injured) vs age-sex matched population expected | Cross-sectional | 29.5 years at military discharge | 100% | >15 years | Self-reported physical health status | ↑ adjusted risk of HTN (RR 2.17 : 1.71–2.62), DM (2.71 : 1.32–4.09) and lipids (2.73 : 1.94–3.52); CVD (RR 1.98 : 0.52–2.33) not significant. No relationship between increasing combat burden to any CVD outcomes or risk factors. |
|
| ||||||||
| MacFarlane et al. 2000 [ | UK Military veterans of Gulf War I (1990–91) | 53416 war veterans | Retrospective cohort | 71.5% <30 years at study enrolment | 97.7% | 8 years | Multiple | No significant difference in all-cause (MRR 1.05 : 0.91–1.21) and CVD mortality (0.74 : 0.49–1.12) among deployed vs nondeployed veterans mortality. |
| 53450 nondeployed military | ||||||||
|
| ||||||||
| Eisen et al. 2005 [ | US Military Gulf War (1991) | 1061deployed war veterans | Cross-sectional | 30.9 years deployed | 78% in both groups | 10 years | Physical health and QOL | No significant difference in adjusted risk of DM (1.52 : 0.81–2.85) or hypertension (0.90 : 0.60–1.33). |
| 1128 nondeployed | 32.6 years non deployed∗ | |||||||
|
| ||||||||
| Granado et al. 2009 [ | US Military (2001–2003) (25% Iraq and Afghanistan) | 4385 combat | Prospective cohort | Not reported | 74.8–86% | 2.7 years | SF-36 questionnaire arterial hypertension | ↑ adjusted incidence of HTN among multiple combat veterans vs. nondeployers (OR 1.33 : 1.07–1.65: |
| 4444 deployed noncombat | But grouped by birth∗ decades | |||||||
| 27232 nondeployed | ||||||||
|
| ||||||||
| Kang et al. 2009 [ | US Gulf War (1991) veterans | 6111 war veterans | Cross-sectional analysis of prospective cohort | 31.5 years for war veterans | 79.9% active 78.2% control | 14 years | Health questionnaires | ↑ adjusted self-reported prevalence of HTN (RR 1.11 : 1.04–1.19), stroke (RR 1.32 : 1.14–1.52), CHD (RR 1.22 : 1.08–1.39) and obesity. No significant difference in DM (RR 1.11 : 0.99–1.25). |
| 3859 veterans not deployed to Persian Gulf | ||||||||
| 33.6 years for control (in 1991) ∗ | ||||||||
|
| ||||||||
| Johnson et al. 2010 [ | US Veterans World War II 40.6% (1941–1945), Korean War 34.6% (1950–1953) Vietnam Conflict 16.8% (1961–1975) | 1178 combat (13.1% veterans) 2127 noncombat (deployed) veterans | Prospective cohort | 19–20 years at enrolment | 100% | 36 years after military entry | Carotid intima-media thickness (CIMT) and carotid plaque | ↑ age-adjusted CIMT in combat veterans (Risk difference 12.79 |
| 57.3 years combat veterans | ||||||||
| 2,042 nonmilitary | ||||||||
| 51.8 years non veterans | ||||||||
| 54.1 years non-combat veterans∗ | ||||||||
|
| ||||||||
| Johnson et al. 2010 [ | US Veterans World War II 40.6% (1941–1945), Korean War 34.6% (1950–1953) Vietnam Conflict 16.8% (1961–1975) | 1178 combat veterans (13.1% injured) | Prospective cohort | 19–20 years at enrolment | 100% | 36 years after military entry | Myocardial infarction unstable angina or CHD-related death | No significant differences in adjusted CHD between combat (13.2%) and noncombat veterans (11.3%), and nonveterans (11.6%); similar ischaemic stroke risk (7.76% vs. 5.22% vs. 6.43%). ↑ prevalence of DM combat vs noncombat but no significant difference in HTN, lipid profiles. |
| 57.3 combat veterans | ||||||||
| 2127 noncombat (deployed) veterans | ||||||||
| 51.8 non veterans | ||||||||
| 2,042 nonmilitary | 54.1 non-combat veterans∗ | |||||||
|
| ||||||||
| Crum-Cianflone et al. 2014 [ | US Military Iraq and Afghanistan wars 2001–2009 | 12280 deployed combat | Prospective cohort | 34.4 years at baseline and mean age at CHD diagnosis 43.1 years (comparative ages not reported) | 84.4% | 5.6 years | Coronary heart disease | Combatants ↑ adjusted (age, sex, race) risk of CHD (OR 1.63 : 1.11–2.40) vs deployed noncombat servicemen but ↓ unadjusted risk of DM and hypertension. |
| 10602 deployed noncombat | ||||||||
| 37143 nondeployed military | ||||||||
|
| ||||||||
| Schlenger et al. 2015 [ | US Vietnam War veterans | 1632 theatre veterans | Retrospective cohort | 41.5 years theatre veterans | >95% | >10 years | ICD codes for causes of death | No significant difference in all cause (16.79% vs. 16.61%), CVD (5.23% vs. 3.81%) or CHD-related (3.02% vs. 2.33%) deaths. |
| 716 Era (noncombat) veteran controls | 40.9 years control | |||||||
|
| ||||||||
| Barth et al. 2016 [ | UK Gulf War (1991) | 621901 Gulf War veterans 746247 noncombat veterans | Retrospective Cohort | 28 years – war veterans | 93% active | 13.6 years | All cause and disease specific mortality (ICD-9) | No difference in adjusted CVD mortality among Gulf War vs noncombat veterans (0.99 : 0.093–1.05) but ↓ all-cause mortality (RR 0.97 : 0.95%–0.99%). ↓ risk of all cause (RR 0.49 : 0.48–0.50) and CVD (RR 0.43 : 0.42–0.45) related mortality in Gulf War veterans vs. US population. |
| 30 years – noncombat veterans∗ | 86.7% control∗ | |||||||
| US general population | Significant | |||||||
|
| ||||||||
| Sheffler et al. 2016 [ | US Vietnam War veterans 1959–1973 | 107 combat veterans | Cross-sectional | 45.4 years – combat | 100% | 10 years | Multiple health outcomes | ↓ adjusted (OR 0.25 : 0.09–0.63; |
| 620 noncombat controls | 46.0 years – noncombat | |||||||
|
| ||||||||
| Thomas et al. 2017 [ | US Military veterans Vietnam war (43.6%) | 564 combat veterans (29.2% injured) | Cross-sectional | 59.0 years – combat | 87.6–93% | >20 years | Validated health questionnaires | ↑ adjusted risk of stroke (OR 1.38 : 1.03–3.33); no difference in adjusted risk of heart attacks, high cholesterol HTN and other heart disease. |
| 61.3 years – noncombat∗ | ||||||||
| 916 noncombat veterans | ||||||||
|
| ||||||||
| Hinojosa 2018 [ | US Military Iraq and Afghanistan Wars 2012–2015 | 14932 combat veterans | Cross-sectional | 56.1 years – veterans 48.8 years – control∗ | 66.3% in military group vs 42% in nonmilitary controls∗ | >1 year | CVD outcomes | ↑ adjusted prevalence of HTN in veterans (OR 1.49 : 1.23–1.81), CHD (OR 1.55 : 1.0–2.40), and heart attacks (2.26 : 1.41–3.62); ↑ rates of stroke among male only veterans (OR 3.32 : 2.03–5.47). |
| 135135 civilians | ||||||||
CHD, coronary heart disease; DM, diabetes mellitus; CVD, cardiovascular disease; HTN, hypertension, Results presented in brackets as odds ratio, relative risk and 95% confidence intervals unless stated; CHD, coronary heart disease; DM, diabetes mellitus; CVD cardiovascular disease; HTN, hypertension; AKA, above knee amputation; ISS, injury severity Score. Results presented in brackets as odds ratio (OR), relative risk (RR), mortality rate ratio (MRR), hazard ratio (HR) and 95% confidence intervals unless stated; ‡refers to studies where proportion with traumatic injury <50%. ∗Detailed demographics for this population either not fully defined or disclosed.
Relative outcomes investigated for included studies and their direction of findings.
| Year | Cardiovascular mortality | CHD-mortality | CHD/MI | Stroke | Abdominal aortic aneurysms | Carotid Intimal thickness | Diabetes mellitus | HTN | Metabolic syndrome | Increased lipid profile | |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||||
| Hrubec and Ryder [ | 1980 | ↑ | ↑ | - | - | - | - | - | - | - | - |
| Labouret et al. [ | 1983 | - | - | - | - | - | - | - | ↑ | - | - |
| Rose et al. [ | 1987 | - | - | - | - | - | - | - | ↑ | - | ↔ |
| Vollmar et al. [ | 1989 | - | - | - | - | ↑ | - | ↔ | ↔ | - | ↔ |
| Yekutiel et al. [ | 1989 | - | - | ↑ | - | - | - | ↑ | ↔ | - | - |
| Lorenz et al. [ | 1994 | - | - | ↔ | ↔ | ↔ | - | ↔ | ↔ | - | ↔ |
| Peles et al. [ | 1995 | - | - | - | - | - | - | ↑ | ↔ | - | ↔ |
| Modan et al. [ | 1998 | ↑ | ↔ | ↔ | - | - | ↔ | ↔ | - | ↔ | |
| Kunnas et al. [ | 2011 | - | ↑ | - | - | - | - | ↔ | - | - | ↔ |
| Shariar et al. [ | 2009 | - | - | - | - | - | - | ↑ | ↑ | - | ↑ |
| Stewart et al. [ | 2015 | - | – | ↑ | - | - | - | ↑ | ↑ | - | - |
| Ejtahed et al. [ | 2017 | - | - | - | - | - | - | - | ↑ | ↑ | ↑ |
|
| |||||||||||
|
| |||||||||||
| Bullman et al. [20] | 1990 | ↓ | - | - | - | - | - | - | - | - | - |
| O'Toole et al. [ | 1996 | - | - | - | - | - | - | ↑ | ↑ | - | ↑ |
| MacFarlane et al. [ | 2000 | ↔ | - | - | - | - | - | - | - | - | - |
| Eisen et al. [ | 2005 | - | - | - | - | - | - | ↔ | ↔ | - | - |
| Granado et al. [ | 2009 | - | - | ↑ | - | - | |||||
| Kang et al. [ | 2009 | - | - | ↑ | ↑ | - | - | ↔ | ↑ | - | - |
| Johnson et al. [ | 2010 | - | - | - | - | - | ↑ | - | - | ||
| Johnson et al. [ | 2010 | - | - | ↔ | ↔ | - | - | ↑ | ↔ | - | ↔ |
| Crum-Cianflone et al. [ | 2014 | - | - | ↑ | - | - | - | ↓ | ↓ | - | - |
| Schlenger et al. [ | 2015 | ↔ | ↔ | - | - | - | - | - | - | - | - |
| Barth et al. [ | 2016 | ↔ | - | - | - | - | - | - | - | - | - |
| Sheffler et al. [ | 2016 | - | - | ↔ | ↔ | - | - | ↓ | ↔ | - | - |
| Thomas et al. [ | 2017 | - | - | ↔ | ↑ | - | - | ↔ | ↔ | - | ↔ |
| Hinojosa [ | 2018 | - | - | ↑ | ↑ | - | - | - | ↑ | - | - |
CHD, coronary heart disease; MI, myocardial infarction; HTN, hypertension; Number refer to study findings in terms of direction of effect in relation to combat/injury versus control population: ↑, significantly increased/positive; ↔, no significant difference; ↓ lower risk; - unreported.
Figure 2Pooled analysis of studies for the outcome of cardiovascular death.
Figure 3Pooled analysis of studies for the outcome of coronary heart disease death.
Summary of key clinical outcomes and strength of evidence.
| Outcome | Study design/number of studies | Findings and direction | Overall strength of evidence |
|---|---|---|---|
|
| |||
| -CTI | Cohort 2, x-sectional 0 | 2 Positive 0 Negative | Moderate ROB; low SOE |
| -Combat only | Cohort 4, x-sectional 0 | 3 Neutral; 1 Negative (lower risk in combat vs control) | Moderate ROB; insufficient SOE |
|
| |||
|
| |||
| -CTI | Cohort 2, x-sectional 0 | 2 Positive | Moderate ROB; low SOE |
| -Combat only | Cohort 1, x-sectional 0 | 1 Negative (lower risk in combat vs control) | Moderate ROB; insufficient SOE |
|
| |||
|
| |||
| -CTI | Cohort 1, x-sectional 3 | 2 Positive; 2 Neutral | High ROB, Insufficient SOE |
| -Combat only | Cohort 2, x-sectional 4 | 3 Positive: 3 Neutral | High ROB, Insufficient SOE |
|
| |||
|
| |||
| -CTI | Cohort 1, x-sectional 1 | 2 Neutral | High ROB, Insufficient SOE |
| -Combat only | Cohort 1, x-sectional 4 | 3 Positive and 2 Neutral | High ROB, Insufficient SOE |
|
| |||
|
| |||
| -Combat only | Cohort 0, x sectional 2 | 2 Positive | High ROB, Insufficient SOE |
| -CTI | Cohort 0, x-sectional 0 | No studies | Insufficient |
|
| |||
|
| |||
| -CTI | Cohort 0, x-sectional 0 | No studies | Insufficient |
| -Combat only | Cohort 1, x-sectional 0 | 1 x Positive; No blinding; No difference in carotid plaque | Moderate ROB, Insufficient SOE |
|
| |||
|
| |||
| -CTI | Cohort 2, x-sectional 6 | 4 Positive 4 Neutral | High ROB, Insufficient SOE |
| -Combat only | Cohort 2, x-sectional 5 | 2 Positive, 3 Neutral, 2 Negative | High ROB, Insufficient: high ROB |
|
| |||
|
| |||
| -CTI | Cohort 1, x-sectional 9 | 5 Positive; 5 Neutral | High ROB, Insufficient SOE |
| -Combat only | Cohort 3, x-sectional: 6 | 4 Positive, 4 Neutral, 1 Negative | High ROB, Insufficient SOE |
|
| |||
|
| x-sectional: 1 | CTI: 1 x Neutral | CTI: Insufficient |
| -CTI | Cohort 0, x-sectional 1 | 1 Positive | Very high ROB, Insufficient |
| -Combat only | No studies | Insufficient | |
|
| |||
|
| |||
| -CTI | Cohort 2, x-sectional 6 | 2 Positive, 6 Neutral (variable or unreported case definition) | High ROB, insufficient SOE |
| -Combat only | Cohort 1, x-sectional 2 | 1 Positive, 2 Neutral | High ROB, insufficient SOE |
CTI, combat related traumatic injury; CHD, coronary heart disease; SOE, strength of evidence; ROB, risk of bias; RR relative risk; OR, odds ratio; Negative studies refer to significantly lower risk of outcome vs control in active group.